Original Article

Primary tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET/CT for the prediction of biochemical recurrence in prostate cancer

Seda Gülbahar Ateş [a],[*], Bedriye Büşra Demirel [b], Esra Kekilli [c], Erdem Öztürk [d], Gülin Uçmak [b]

[a] Department of Nuclear Medicine, Hitit University Erol Olçok Training and Research Hospital, Çorum, Turkey
[b] Department of Nuclear Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
[c] Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey
[d] Department of Urology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

ARTICLE INFO

ABSTRACT

Purpose: The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.

Methods: 51 patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.

Results: 29 (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level ($P = .050$), GLCM-sum variance ($P = .019$), and GLCM-cluster prominence ($P = .050$) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level ($P = .009$) and GLCM-sum variance ($P = .004$) were found as independent predictors of BCR in the multivariate analysis.

Conclusion: Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.

Heterogeneidad del tumor primario en la PET/TC con PSMA [68Ga]Ga previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata

RESUMEN

Objetivo: El objetivo de este estudio es investigar el valor del análisis de textura de tumores primarios en PET con PSMA [68Ga]Ga pretratamiento en la predicción del desarrollo de recurrencia bioquímica (BCR) en pacientes con cáncer de próstata que se sometieron a terapias definitivas.

Métodos: Se incluyeron en el estudio 51 pacientes con adenocarcinoma de próstata a los que se les realizó una PET/TC con [68Ga]Ga-PSMA-11 pretratamiento y se sometieron a radioterapia (RT) definitiva o prostatectomía radical (PR). Se registraron las características demográficas, clínico-patológicas, la presencia de BCR y la última fecha de seguimiento de los pacientes. Los parámetros de PET texturales y convencionales (valor máximo de captación estandarizado (SUVmax), lesión total-PSMA (TL-PSMA) y volumen tumoral de PSMA (PSMA-TV)) se obtuvieron a partir de imágenes PET/CT utilizando el programa LifeX. Los parámetros se agruparon utilizando el índice de Youden en el análisis ROC. Los factores que predicen el BCR se determinaron mediante análisis de regresión de Cox.

Resultados: 29 (56,9%) pacientes recibieron RT curativa primaria, mientras que los 22 (43,1%) pacientes restantes se sometieron a PR. 5 (22,7%) pacientes con PR y 3 (10,3%) pacientes con RT curativa desarrollaron BCR durante el seguimiento. El nivel de gris mínimo BASADO EN LA INTENSIDAD ($P = ,050$), la varianza de la suma GLCM ($P = ,019$) y la prominencia del grupo GLCM ($P = ,050$) se asociaron con BCR en el análisis univariado. El nivel de gris mínimo BASADO EN LA INTENSIDAD ($P = ,009$) y la varianza de la suma GLCM ($P = ,004$) fueron predictores independientes de BCR en el análisis multivariado.

---

* Corresponding author.
E-mail address: sdsdglbhr@gmail.com (S. Gülbahar Ateş).

Conclusión: La heterogeneidad tumoral en la PET con PSMA [68Ga]Ga previa al tratamiento se asocia con un alto riesgo de BCR en pacientes con CaP que se sometieron a terapias definitivas.

Introduction

Prostate cancer (PCa) is the second most common cancer after lung cancer in men worldwide according to the World Health Organization GLOBOCAN 2020 database.[1] The clinical presentation of PCa reveals a wide spectrum, ranging from low-risk localized disease that could undergo active surveillance to high-risk metastatic disease that causes mortality and morbidity.[2,3] Furthermore, the patients with organ-confined disease at the time of diagnosis might have substantially different oncologic outcomes during the follow-up. Between 27% and 53% of all patients undergoing radical prostatectomy (RP) or radiotherapy (RT) develop a rising prostate specific antigen (PSA).[4]

Various biomarkers and risk stratification methods have been seeking for the prediction of outcomes in PCa. Especially ISUP grade-gleason score (GS), total PSA (tPSA), and clinical T stage are used widely for this purpose.[4,5] The risk classification systems for biochemical recurrence (BCR) based on these parameters are recommended and utilized universally in localized and locally-advanced PCa patients.[4,6] However, there is still a need for additional prognostic biomarkers to predict BCR and guide treatment accordingly in PCa management.

PCa is a heterogeneous disease in multiple layers such as morphologic, genotypic, and phenotypic. Histo-morphologic and molecular tumor characteristics exhibit a prominent diversity between different patients (inter-patient heterogeneity), different tumor foci in a patient (inter-tumoral heterogeneity), and within a given tumor (intra-tumoral heterogeneity). It was highlighted that these heterogeneities could result in distinct cellular phenotypes that contribute to the overall biological behavior of a cancer.[7–9] It is known that tumor heterogeneity is associated with treatment resistance, prognosis, and survival.[10] Thus, the determination of tumor heterogeneity non-invasively might be a promising approach for personalized medicine. In various cancers, different molecular imaging modalities, depending on the radiopharmaceutical agents used, may be helpful in the non-invasive evaluation of different molecular properties-heterogeneities such as glucose metabolism and receptor expression.

Prostate specific membrane antigen (PSMA) targeting positron emission tomography (PET) agents, especially gallium-68 ([68Ga]Ga)-PSMA, are widely used in staging and restaging of patients with PCa. [68Ga]Ga-PSMA PET has been demonstrated to be superior to conventional imaging modalities in terms of staging and evaluating BCR in PCa.[11,12] Various studies have widely evaluated the prognostic value of the semi-quantitative parameters of PSMA expression such as maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV). Although their relationship with varied prognostic clinicopathologic features (GS, PSA, the presence of metastatic lymph node or distant metastasis, and pathologic T stage, etc.) have been demonstrated in PCa, their prognostic ability to predict the disease course appears to be limited for now.[13–16] Therefore, improved imaging biomarkers and their combination with clinicopathologic features are required for effective patient management.

Radiomics, which is a rapidly growing research field, can be defined as the high-throughput extraction, analysis, and interpretation of quantitative image features from medical images. It provides a large amount of unique data that cannot be evaluated with the naked eye, even by experts. Texture analysis is a featured radiomics technique that evaluates the distribution and interconnection of grayscale levels in pixels or voxels. Texture analysis contains features included in radiomics analysis. It provides an objective quantitative assessment of tumor heterogeneity in vivo. Therefore, the aim of texture analysis is to generate diagnostic, predictive, and prognostic models using imaging biomarkers to answer a certain clinical question, such as the discrimination of benign and malign lung nodules, the determination of aggressive tumor profiles, and patient outcomes (survival, response to therapy, etc.).[17–19]

Numerous studies on the texture analysis of computer tomography (CT), magnetic resonance imaging (MRI), and PET images in various cancer types have revealed promising results. While the number of studies about texture analysis of PSMA PET in PCa is limited, the majority of them are about the prediction of low-high risk classification, the presence of pelvic metastatic lymph nodes, and ISUP grade-GS.[20–23] Our hypothesis in the present study was that the texture features of primary prostate tumors on pre-treatment [68Ga]Ga-PSMA PET might predict the development of BCR in the PCa patients who underwent definitive therapies. It may be beneficial for therapy management and intensification in those patients. Accordingly, the aim of this study is to evaluate the role of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of BCR in PCa patients who underwent definitive RT or RP.

Material and method

Patient population

This retrospective study was approved by the local ethics committee (no: 2023-01/17). The need for informed consent was waived. In the present study, the patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT were evaluated. In our center, patients with a Gleason score of ≥ 7 or total PSA ≥ 10.0 ng/mL (intermediate or high-risk groups) are eligible for pre-treatment [68Ga]Ga-PSMA PET/CT. Additionally, patients with radiologically suspicious findings may undergo pre-treatment [68Ga]Ga-PSMA PET/CT imaging.

The patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT with a PSMA-positive primary prostate tumor without distant metastases, who have undergone definitive RT or RP, and with a sufficient follow-up duration (at least 6 months) were included in the present study. The patients who received treatment (chemotherapy, RT, surgery, etc.) for PCa before [68Ga]Ga-PSMA-11 PET/CT or who had a second primary malignancy were excluded from the study.

Clinicopathologic features

The hospital information system was utilized to evaluate the patients' demographic characteristics and clinical histories. The values of tPSA at the diagnosis, nadir tPSA after definitive therapies, alkaline phosphatase, and lactate dehydrogenase were recorded. GS, ISUP grades, the percentages of malignancy on biopsy, the num-

Figure 1. Texture analysis of [68Ga]Ga-PSMA images (A. Coronal, B. Sagittal, C. Axial, D. Axial images with VOİ (red arrow)).
Patient images were uploaded in DİCOM format (A-B-C-D). Volume of interests (VOİ) of primary prostate tumors were drawn semi-automatically. Primary tumor lesions were segmented by using 40% of the maximum value in the VOI as a threshold (D.). Texture features were extracted from tumor VOIs.

bers of positive core biopsies and cores with ISUP grade 4−5, the positivity of surgical margin, pathologic N and T stages, the presence of perineural invasion, extra-prostatic extension, and seminal vesicle invasion were evaluated from pathology reports. The risk groups (low risk: tPSA < 10 and ISUP grade 1, intermediate risk: tPSA = 10–20 or ISUP grade 2/3, and high risk: tPSA > 20 or ISUP grade 4/5) were assessed according to ISUP grades and the values of tPSA at the diagnosis. RT and surgery plans of the patients were recorded. Consequently, the development of BCR during the follow-up was evaluated. BCR is defined as a rise by 2 ng/mL or more above the nadir PSA after RT and consecutive PSA detectability (≥0.2 ng/mL) after RP. The time to BCR was calculated from the date of definitive therapies. Patients were followed until death or last medical visit.

PET/CT acquisition

[68Ga]Ga-PSMA-11 was given intravenously in a dose of 0,05 mCi/kg body weight. The range of injected activity was 3.5–6.0 mCi. PET/CT images were obtained by three-dimensional Siemens Biograph True Point 6 PET/CT device at least 60 min after [68Ga]Ga-PSMA-11 injection. PET scanner and 3 mm sliced multidetector CT scanner obtained simultaneous images in the same session. The duration of each bed was 3.5 min. Imaging was performed from the vertex to the mid-thigh. Low-dose CT images without intravenous iodinated contrast were performed for attenuation correction and anatomical correlation.

Image analysis

In this study, the Local Images Features Extraction (LIFEx) software was used for texture analysis. [68Ga]Ga-PSMA-11 PET/CT

images of the patients uploaded LIFEx version 7.3 in DICOM formate.[24] LIFEx is a comprehensive software package designed for the analysis of medical images, specifically tailored for radiomics and texture analysis. It is an easy-to-use freeware. It provides a robust platform for extracting a wide range of quantitative features from medical imaging data, including PET, CT, and MRI scans.

In the present study, on the PET images, volume of interests (VOIs) with a threshold of 40% of the SUVmax was drawn manually in the region of the prostate gland that visually showed increased [68Ga]Ga-PSMA-11 uptake when the PET image was set to 0–7.5 SUVmax intensity by an experienced nuclear medicine specialist (Fig. 1). The conventional PET parameters as SUVmax, SUVmean, PSMA-TV, and TL-PSMA (TV-PSMAxSUVmean) were measured. LIFEx was run by using the following input parameters: 64 grey levels to resample the ROI content which was performed using absolute resampling in 64 bins and SUV units between a minimum of 0 and a maximum of 40. Spatial resampling was set to $4 \times 4 \times 4$ mm. The features extracted from PET images contain first-order parameters (morphological, intensity-based, local intensity-based, and intensity histogram) and second-order texture parameters (grey level co-occurrence matrix (GLCM), grey-level run length matrix (GLRLM), neighborhood grey tone difference matrix (NGTDM), grey-level size zone length matrix (GLSZM)) (Table 1). The Image Biomarker Standardization Initiative (IBSI) compliant features were included in analyses. Additionally, miTNM stages of patients were evaluated on [68Ga]Ga-PSMA-11 PET/CT as described in the literature.[25]

Statistical analysis

Statistical analyses were carried out using the SPSS software version 25. Optimal cut-off values were calculated using the Youden's

Table 1
The texture parameters extracted from ^{68}Ga PSMA PET images.

FIRST ORDER FEATURES	Morphological	Surface Area, Surface to volume ratio, Compactness, Spherical disproportion, Centre of mass shift, Integrated intensity
	Intensity based	Mean, Variance, Skewness, Kurtosis, Median, Minimum grey level, 10th percentile, 90th percentile, Maximum grey level, Interquartile range, Range, Robust mean absolute deviation, Coefficient of variation, Area under curve-CSH, Energy, Root mean square
	Local intensity based	Global intensity peak 1 mL, Local intensity peak
	Intensity histogram	Mean, Variance, Skewness, Kurtosis, Mean absolute deviation, Robust mean absolute deviation, Median absolute deviation, Coefficient of variation, Quartile coefficient of dispertion, Entropy log 10, Entropy log2, Area under curve-CSH, Uniformity, Maximum histogram gradient, Minimum histogram gradient
SECOND ORDER FEATURES	Grey-level co-occurrence matrix (GLCM)	Joint variance, Joint entropy log 2, Difference variance, Difference entropy, Sum average, Sum variance, Sum entropy, Contrast, Dissimilarity, Normalized inverse difference, Normalized inverse difference moment, Inverse variance, Correlation, Autocorrelation, Cluster shade, Cluster prominence
	Grey-level run length matrix (GLRLM)	Short runs emphasis (SRE), Long runs emphasis (LRE), High grey level run emphasis (HGLRE), Short run low grey level emphasis (SRLGLE), Short run high grey level emphasis (SRHGLE), Long run low grey level emphasis (LRLGLE), Long run high grey level emphasis (LRHGLE), Grey level non-uniformity (GLNU), Run length non-uniformity (RLNU)
	Neighborhood grey-level difference matrix (NGTDM)	Coarseness, Contrast, Complexity, Strength
	Grey-level zone length matrix (GLSZM)	Small zone emphasis (SZE), Large zone emphasis (LZE), Low gray level zone emphasis (LGLZE), High grey level zone emphasis (HGLZE), Small zone low grey level emphasis (SZLGE), Small zone high grey level emphasis (SZHGLE), Grey level variance (GLV), Zone size variance (ZSV), Zone size entropy (ZSE)

index (sensitivity + specifity-1) from the receiver-operating characteristics (ROC) curve analyses. Conventional PET parameters and texture features were split into two groups based on the optimal cut-off values. Cox regression analyses were performed to identify predictors of BCR in univariate and multivariate analyses. Highly correlated variables (r > 0.7) were excluded from the analyses to prevent multicollinearity. BCR-free survival analysis was performed using the Kaplan-Meier method. An overall 5% type-1 error level was used to infer statistical significance. Kaplan-Meier curves were exported from SPSS and subsequently combined into a single plot using Inkscape v.1.3.2, a free and open-source vector graphics editor.

Results

51 patients with PCa were included in the present study. The clinicopathologic features of the patients were shown in Table 2. The mean age of the patients was 67.2 ± 6.7 (54–82) years. The total numbers of the patients with low/intermediate-risk and high-risk PCa were 17 (33.3%) and 34 (66.7%), respectively. 29 (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP.

The mean duration of follow-up was 23.3 ± 12.7 months. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. However, the difference was not statistically significant ($P = .268$). The mean BCR-free survival was 48.1 ± 2.8 months (95% CI. 42.6–53.6). It was found that BCR-free survival was 95.6% at 1 year, 86.8% at 2 years, and 75.7% at 3 years (Fig. 2, the red curve).

It is found that there is no significant association between clinicopathologic features, conventional PET parameters and the development of BCR in univariate analyses (all $P > .05$, Table 3). The parameters significantly associated with BCR in the univariate and multivariate analyses were shown in Table 4. Among the first-order features, only the INTENSITY-BASED-minimum grey level was associated with BCR in the univariate analyses ($P = .050$). There is no statistically significant association between the development of BCR and the other first-order features in the univariate analyses (Supplementary Table 1). The parameters of GLCM-sum variance ($P = .019$) and GLCM-cluster prominence ($P = .050$) were significantly associated with the development of BCR in the univariate analyses (Table 4). However, there is no significant

association between the other second-order features and the development of BCR in the univariate analyses (Supplementary Table 2). INTENSITY-BASED-minimum grey level ($P = .009$) and GLCM-sum variance ($P = .004$) were found as independent predictors of BCR in the multivariate analysis applied by including the parameters of INTENSITY-BASED-minimum grey level, GLCM-sum variance, and GLCM-cluster prominence (Table 4). In the Kaplan-Meier analysis, it is demonstrated that a lower value of GLCM-sum variance (≤ 52 vs >52 unit, mean 28.6 ± 3.2 vs 53.2 ± 2.6 months, $P = .007$, Fig. 2, blue curves) and a higher value of INTENSITY-BASED-minimum grey level (>58 vs ≤ 58 unit, mean 34.1 ± 3.1 vs 54.8 ± 2.2 months, $P = .020$, Fig. 2, green curves) were associated with a poorer BCR-free survival.

Discussion

The early recognition of PCa patients who have a poorer outcome and will develop BCR during the follow-up is crucial for treatment intensification or avoidance from unnecessary treatments and their side effects. Although radiomics analysis of MRI has been evaluated for the prediction of BCR in PCa patients by many studies,[26] a limited number of studies on radiomics analysis of PSMA PET images have existed on this topic.[27] In the present study, when clinicopathologic features, conventional, and textural PET parameters were examined together to predict the development of BCR in PCa patients who underwent definitive therapies, only some texture parameters obtained from PSMA PET images had a robust value for the prediction of BCR in these patients.

Conventional PET parameters related to PSMA expression (SUVmax, SUVmean, PSMA-TV, TL-PSMA) and miTNM staging based on PSMA PET imaging have been evaluated for the prediction of BCR in PCa patients by various studies.[16,28–31] In the present study, it was demonstrated that there is no significant association between these parameters and the development of BCR in PCa patients who underwent definitive RT or RP. Unlike our study, the study by Wang et al. has shown that miT and miN stages, SUVmean, SUVmax, and PSMA-TV of prostatic lesions on pre-operative [68Ga]Ga-PSMA PET were associated with BCR-free survival, and also miT stage and PSMA-TV are independent predictors for BCR-free survival in PCa patients who underwent RP.[16] Similarly, miT stage and SUVmax on PSMA ligand PET/CT were indicated as superior predictors for BCR in PCa patients who under-

Table 2
Clinicopathologic features of the patients.

Clinicopathologic features		mean ± SD or median (min−max) or N (%)
Age		67.2 ± 6.7 (54−82)
Total PSA (ug/L)		12.85 (3.3−323.0)
ISUP grade	Grade 1−3	24 (47.1%)
	Grade 4−5	27 (52.9%)
Risk stratification	Low-intermediate	17 (33.3%)
	High	34 (66.7%)
The number of positive core biopsy		7 (1−12)
The number of cores with ISUP grade 4−5		1 (0−12)
The presence of perineural invasion	Positive	25 (49.0%)
	Negative	5 (9.8%)
	Unknown	21 (41.2%)
Alkaline phosphatase		65.6 (33.0−175.0)
Lactate dehydrogenase		182.9 ± 27.8 (127−149)
THE FİNDİNGS OF PRE-TREATMENT ^{68}GA PSMA PET/CT		
Primary tumor		
● SUVmax (g/mL)		11.6 (3.9−91.2)
● SUVmean (g/mL)		6.8 (2.1−47.5)
● PSMA-tumor volume (PSMA-TV) (cm3)		10.4 (1.3−49.8)
● Total lesion-PSMA (TL-PSMA)		73.0 (17.6−2350.47)
miT stage		
● miT2		31 (60.8%)
● miT3-4		20 (39.2%)
miN stage		
● miN0		33 (64.7%)
● miN1		18 (35.3%)
Primary Curative Radiotherapy		29 (56.9%)
● Pelvic radiotherapy		23 (79.3%)
● Boost application for pelvic lymph nodes		14 (48.3%)
● Anti-androgen deprivation therapy (ADT) with radiotherapy		
○ Neoadjuvant ADT		23 (79.3%)
○ Concurrent ADT		5 (17.2%)
○ No ADT		1 (3.4%)
Radical prostatectomy + Pelvic lymph node dissection		22 (43.1%)
The pathologic findings of radical prostatectomy (n = 19)		
● Extra-prostatic expansion		13 (68.4%)
● Seminal vesicle invasion		8 (42.1%)
● The positivity of surgical margin		8 (42.1%)
● The positivity of pathologic lymph nodes (pN+)		4 (21.1%)
● Pathologic T stage		
pT2		4 (21.1%)
pT3		15 (78.9%)
Nadir tPSA (ug/L)		0.015 (0.0−0.90)
The duration of follow-up (month)		23.3 ± 12.7
Biochemical recurrence	Radiotherapy	3/29 (10.3%)
	Radical prostatectomy	5/22 (22.7%)
	Total	8/51 (15.7%)

Table 3
Univariate analysis results of clinicopathologic features and conventional PET parameters.

Parameters	P value	Parameters	P value
Age	.364	Alkaline phosphatase	.130
ISUP grade	.650	Lactate dehydrogenase	.746
tPSA	.259	Hormonotherapy plan	.744
Risk stratification (low, intermediate, high)	.502	Boost RT	.539
Curative therapy (RT vs RRP)	.149	Pelvic RT	.078
Pelvic lymph node dissection	.877	Primary tumor SUVmax	.380
Nadir tPSA	.068	Primary tumor SUVmean	.337
The percentage of malignancy on biopsy	.789	Primary tumor PSMA-TV	.545
The number of positive core biopsy	.974	Primary tumor TL-PSMA	.445
The number of cores with ISUP grade 4−5	.886	miT stage	.499
The presence of perineural invasion	.598	miN stage	.151
The presence of extraprostatic expansion	.568		
The presence of seminal vesicle invasion	.366		
Surgical margin positivity	.628		
pN stage (+/-)	.897		
pT stage	.606		

Table 4
The parameters significantly associated with BCR in the univariate and multivariate analyses.

|	Univariate analysis			Multivariate analysis		
	OR	95% C.I.	P value	OR	95% C.I.	P value
INTEN-BASED-minimum grey level	8.174	(0.996−67.04)	.050	38.636	(2.44−609.91)	.009
GLCM-sum variance	0.147	(0.030−0.729)	.019	0.036	(0.004−0.355)	.004
GLCM-cluster prominence	3.971	(0.988−15.96)	.050			

Figure 2. Kaplan-Meier curves illustrating BCR-free survival in all patients (red curves). Kaplan-Meier curves according to GLCM-sum variance (blue curves) and INTENSITY BASED-minimum grey level (green curves).

went RP.[29] Furthermore, SUVmax values-PSMA uptakes of primary tumors were found to be associated with BCR in PCa patients who underwent RP by several studies.[28–30] However, consistent with our study, in the study by Spohn et al., SUVmax values extracted from the prostate were not associated with BCR-free survival in PCa patients who received definitive RT.[31] Although it is known that PSMA expression is correlated with histologic tumor grade and plays a complex role in tumor aggressive behavior,[28,32,33] these discrepancies among the results of the studies might be due to their diverse patient populations and study designs. In the present study, in particularly the PCa patients who underwent all definitive therapies (RP or definitive RT) were examined together. Thus, our aim was to determine predictors of the aggressive tumor behavior related to BCR in these patient populations regardless of definitive therapy options and to obtain an initial risk stratification. Consequently, in the present study, conventional PET parameters were not associated with the development of BCR, whereas only some texture parameters were independent predictors for BCR in PCa patients who underwent definitive therapies.

Texture analysis of medical images reflects the underlying spatial variation and heterogeneity of voxel intensities within a tumor. In recent years, it has increasingly supported that texture analysis might put forth valuable predictive and prognostic knowledge in several malignancies. Consistent with the literature stream, the present study has shown that selected texture parameters derived from pre-treatment [68Ga]Ga-PSMA PET have a prominent predictive role in the development of BCR in PCa patients. In our study, while the INTENSITY-BASED-minimum grey level, GLCM-

sum variance, and GLCM-cluster prominence were found to be associated with the development of BCR in univariate analyses, only the parameters of INTENSITY-BASED-minimum grey level and GLCM-sum variance were found as independent predictors of BCR in the multivariate analysis.

Texture features are digitalization of gray intensity values of pixels or voxels at defined levels such as matrixes. Each feature attempt to describe the various heterogeneity tendencies like asymmetry, similarity, randomity, diversity, etc. The intensity-based features describe how grey levels within the region of interest (ROI) distribute, whereas the GLCM is a matrix that expresses how combinations of discretized grey levels of neighboring pixels or voxels in a 3D volume along one of the image directions. The GLCM-sum variance is the quantification of the deviation from the average voxel gray level value, which reflects the similarity in gray level values. The GLCM-cluster prominence expresses the asymmetry in voxel gray level values. Similarly, GLCM-joint entropy log2 is a measure of randomness, and GLCM-NGLNU measures the variability of gray level intensity.[34] Consequently, in the light of our study, all these texture features, especially GLCM-sum variance, might provide in-depth information about tumor heterogeneity and aggressive behavior in PCa patients who underwent definitive therapies. To the best of our knowledge, there is no study on pre-treatment [68Ga]Ga-PSMA in exactly the same topic and study design. However, Marturano et al. have researched the radiomics analysis of pre-treatment ^{18}F-Fluorometilcholine PET to identify patients who underwent definitive therapies at high risk of BCR. Although with a different agent than [68Ga]Ga-PSMA, the study

showed that BCR prediction performance further increases when clinical data are complemented with radiomic features.[35] In the present study, a lower value of GLCM-sum variance was associated with a poorer BCR-free survival. In the line of the result, the study about the prediction of clinically significant PCa using radiomics features of pre-biopsy of multiparametric MRI has demonstrated that a lower value of GLCM-sum variance on T2 weighted MRI was one of the most critical features.[36] Even though the imaging modalities and outcomes in these studies are different, these results have shown that GLCM-sum variance might be related with tumor heterogeneity in PCa. However, it should be kept in mind that heterogeneity in different radiopharmaceuticals and imaging modalities may have dissimilar biological meanings.

This study has some main limitations. Firstly, the study is a retrospective, one-center study with a small number of patients. The patient population was heterogeneous in terms of clinicopathologic features and therapy protocols. Secondly, the machine-learning methods, cross-validation, and external validation have not been applied because of the limited number of patients. Before regular use in the clinic, this method should be thoroughly investigated through prospective multicenter studies with larger cohorts. Finally, the true relationship between texture parameters and biological tumor features remains uncertain and the histopathologic-genetic basics of features could not be researched because of the nature of the study.

Conclusion

Our study has shown that tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies, despite the limitations. In the future, the selected texture parameters derived from pre-treatment [68Ga]Ga-PSMA PET might have great potential in initial risk stratification for the prediction of BCR in patients who underwent definitive therapies.

Declaration of interests

None.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.remnie.2024.500032.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: CA Cancer J Clin. 2021;71(3):209–49.
2. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645–57.
3. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366–81.
4. Urology EAo. EAU guidelines. In: Edn. presented at the EAU annual congress milan 2023. Arnhem, the Netherlands. 2023.
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.
6. Schaeffer E, Srinivas S, An Y. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1. 2023. 2023.
7. Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92.
8. Mitchell T, Neal DE. The genomic evolution of human prostate cancer. Br J Cancer. 2015;113(2):193–8.
9. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. 2015;33(2):85–94.
10. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64.
11. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.
12. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.
13. Aksu A, Vural Topuz Ö, Yılmaz G, Çapa Kaya G, Yılmaz B. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses. Ann Nucl Med. 2022;36(3):310–8.
14. Vetrone L, Mei R, Bianchi L, Giunchi F, Farolfi A, Castellucci P, et al. Histology and PSMA expression on immunohistochemistry in high-risk prostate cancer patients: comparison with (68)Ga-PSMA PET/CT features in primary staging. Cancers (Basel). 2023;15(6).
15. Xie Y, Li C, Zhang L, Zang S, Yu F, Wang S, et al. [(68)Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer]. Nan Fang Yi Ke Da Xue Xue Bao. 2022;42(8):1143–8.
16. Wang H, Amiel T, Würnschimmel C, Langbein T, Steiger K, Rauscher I, et al. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Res. 2021;11(1):76.
17. Hatt M, Krizsan AK, Rahmim A, Bradshaw TJ, Costa PF, Forgacs A, et al. Joint EANM/SNMMI guideline on radiomics in nuclear medicine: jointly supported by the EANM Physics Committee and the SNMMI Physics, Instrumentation and Data Sciences Council. Eur J Nucl Med Mol Imaging. 2023;50(2):352–75.
18. Litvin AA, Burkin DA, Kropinov AA, Paramzin FN. Radiomics and digital image texture analysis in oncology (Review). Sovrem Tekhnologii Med. 2021;13(2):97–104.
19. Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present. . . any future? Eur J Nucl Med Mol Imaging. 2017;44(1):151–65.
20. Solari EL, Gafita A, Schachoff S, Bogdanović B, Villagrán Asiares A, Amiel T, et al. The added value of PSMA PET/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging. 2022;49(2):527–38.
21. Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9(9):2595–605.
22. Ghezzo S, Mapelli P, Bezzi C, Samanes Gajate AM, Brembilla G, Gotuzzo I, et al. Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(8):2548–60.
23. Feliciani G, Celli M, Ferroni F, Menghi E, Azzali I, Caroli P, et al. Radiomics analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the prediction of Prostate Cancer ISUP Grades: preliminary results of the BIOPSTAGE trial. Cancers (Basel). 2022;14(8):1888.
24. Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786–9.
25. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626–38.
26. Ghezzo S, Bezzi C, Presotto L, Mapelli P, Bettinardi V, Savi A, et al. State of the art of radiomic analysis in the clinical management of prostate cancer: a systematic review. Crit Rev Oncol Hematol. 2022;169:103544.
27. Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, et al. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET/MRI. Eur J Nucl Med Mol Imaging. 2021;48(6):1795–805.
28. Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, et al. (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate- or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. J Nucl Med. 2022;63(12):1822–8.
29. Qiu X, Chen M, Yin H, Zhang Q, Li H, Guo S, et al. Prediction of biochemical recurrence after radical prostatectomy based on preoperative (68)Ga-PSMA-11 PET/CT. Front Oncol. 2021;11:745530.
30. Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49(9):3289–94.
31. Spohn SKB, Birkenmaier V, Ruf J, Mix M, Sigle A, Haehl E, et al. Risk factors for biochemical recurrence after PSMA-PET-guided definitive radiotherapy in patients with De Novo Lymph Node-Positive Prostate Cancer. Front Oncol. 2022;12:898774.
32. Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018;8(1):4254.
33. Hyväkkä A, Virtanen V, Kemppainen J, Grönroos TJ, Minn H, Sundvall M. More than meets the eye: scientific rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in metastatic prostate cancer and beyond. Cancers (Basel). 2021;13(9).
34. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quanti-

tative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328–38.

35. Marturano F, Guglielmo P, Bettinelli A, Zattoni F, Novara G, Zorz A, et al. Role of radiomic analysis of [(18)F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging. Eur Radiol. 2023;33(10):7199–208.

36. Ogbonnaya CN, Zhang X, Alsaedi BSO, Pratt N, Zhang Y, Johnston L, et al. Prediction of clinically significant cancer using radiomics features of pre-biopsy of multiparametric MRI in men suspected of prostate cancer. Cancers (Basel). 2021;13(24).